The tumor suppressor p53, encoded by the TP53 gene, is recognized as the guardian of the human genome because it regulates many downstream genes to exercise its function in cell cycle and cell death. Recent studies have revealed that several microRNAs (miRNAs) are important components of the p53 tumor suppressor network with miR-125b and miR-504 directly targeting TP53. In this study, we use a screening method to identify that two miRNAs (miR-25 and miR-30d) directly target the 3 0 UTR of TP53 to downregulate p53 protein levels and reduce the expression of genes that are transcriptionally activated by p53. Correspondingly, both miR-25 and miR-30d adversely affect apoptotic cell death, cell cycle arrest and cellular senescence. Inhibition of either miR-25 or miR-30d expression increases endogenous p53 expression and elevates cellular apoptosis in several cell lines, including one from multiple myeloma that has little TP53 mutations. Thus, beyond miR-125b and miR-504, the human TP53 gene is negatively regulated by two more miRNAs: miR-25 and miR-30d.
Introduction
Tumorigenesis is widely accepted as a multistep process that requires activation of oncogenes and inactivation of tumor suppressor genes (Hanahan and Weinberg, 2000) . Tumor protein p53 (p53) is recognized as the guardian of the human genome. It responds to diverse stressors to transactivate many downstream genes, such as p21, Bax and Puma, which are critical for apoptotic cell death, cell cycle arrest and cellular senescence (Riley et al., 2008; Vogelstein et al., 2000; Kruse and Gu, 2009; Vousden and Prives, 2009) . Restoring p53 function alone is sufficient to cause regression of several types of tumors in mice (Ventura et al., 2007; Xue et al., 2007) , supporting the notion that p53 function has to be disrupted for tumor development. Indeed, somatic mutations of TP53, the gene that encodes p53, are estimated to occur in B50% of all human cancers. In many other cancers, TP53 is inactivated indirectly through amplification or overexpression of the MDM2 gene encoding the murine double minute 2 (Mdm2) protein or its homolog MDM4. This mechanism is reported to occur in B10-20% of all cancers (Toledo and Wahl, 2006) . Other mechanisms of p53 inactivation occur at much lower frequencies and include allelic deletion of CDKN2A encoding the p14 ARF protein, viral protein inactivation of p53, or mislocation of p53 into the cytoplasm (Vogelstein et al., 2000) . We reasoned that, if p53 malfunction is required for all cancers, there are a significant number of cancers with unknown p53 inactivation mechanisms and that a newly discovered class of non-coding regulatory RNA molecules called microRNAs (miRNAs) might be potential inhibitors of p53 gene expression.
miRNAs are short 20-25 nucleotide RNA molecules that negatively regulate gene expression by targeting the 3 0 UTRs of mRNAs (Bartel, 2004) . Several reports shed light on the involvement of miRNAs in the p53 pathway. Agami and colleagues have shown that miR-372 and miR-373 permit proliferation and tumorigenesis of primary human cells that harbor both oncogenic RAS and active wild-type (wt) p53. They further demonstrated that these two miRNAs neutralize p53-mediated CDK inhibition by negatively regulating the tumor suppressor LATS2 gene (Voorhoeve et al., 2006) . He et al. (2007) profiled miRNA gene expression in wt and p53-deficient cells and found that the miR-34 gene family (including miR-34a, b and c) was among the most upregulated in wt p53 cells. They further found that miR-34s were transcriptionally activated by p53 and that ectopic expression of miR-34 induced cell cycle arrest by downregulating the expression of CDK4 and other genes (He et al., 2007) . The finding that miR-34s are critical components of the p53 network has been independently corroborated by several other laboratories (Bommer et al., 2007; Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007; Tarasov et al., 2007) . Taken together, these results support a pivotal downstream role of miRNAs in the regulation of the p53 pathway.
The initial dissection of human miRNA function, mostly by identifying target genes and characterizing related phenotypes, has been approached using three distinct methods. The first approach, as exemplified by let-7 (Johnson et al., 2005) targeting RAS, is to explore the human homolog of a miRNA with known function in nematodes or other organisms. The second, as exemplified by miR-34a (He et al., 2007) targeting genes in the p53 network, is to profile miRNA expression in disease end points, tissues or cells treated with various agents before selecting a single miRNA for examination. The last approach as exemplified by miR-372 and miR-373 (Voorhoeve et al., 2006) targeting LATS2 is to screen for a desired phenotype using a pooled miRNA library. The method of let-7 and RAS is not applicable for human TP53, as the 3 0 UTR of human p53 mRNA is not homologous to that of mouse or other lower eukaryotes. The second approach, that is, general expression profiling of most human tumor tissues, might miss the miRNA-TP53 interaction, as p53 is mutated in B50% of cancers. Park et al. (2009) used a reporter assay to screen 91 miRNAs and found that the miR-29 family can upregulate p53 by targeting p85a and CDC42, although it is vague about how p85a and CDC42 activate p53 (Park et al., 2009) . miR-125b, a brain-enriched microRNA, was identified as a bona fide negative regulator of p53 in both zebrafish and humans (Le et al., 2009 ). More recently, Hu et al. (2010) showed that miR-504 directly represses p53 expression and function in human cell lines. Here, we report the development of a two-tier screening assay to identify miRNA that negatively regulates p53 signaling through direct interaction with TP53 3 0 UTR. We screened over 400 miRNAs and found that miR-25 and miR-30d downregulate p53 expression and interfere with its function in cell cycle arrest, apoptosis and senescence. These findings showed that multiple miRNAs directly inhibit p53 expression and function by interacting with its 3 0 UTR, adding a new layer of complexity of p53.
Results

Dual-reporter screening to identify miRNAs targeting TP53 in 293T cells
We performed a screen using the tier-1 assay ( Figure 1a ) to determine whether any of the 366 miRNA constructs carrying 419 mature miRNAs modulate the basal p53 activity in 293T cells (Supplementary Data Set 1). We found a large number of miRNAs that activate or suppress p53 signaling, as judged by alteration of the luc/Rluc readout. Overall, there were 105 miRNAs upregulating and 65 downregulating the basal luc expression by more than 25%. The 25% cutoff was used as it is the minimum threshold observed in two previously published articles on miRNA-3 0 UTR interactions (Lewis et al., 2005; Miranda et al., 2006) . Next, we performed computational analyses to predict which miRNAs might target the human TP53 gene with four commonly used miRNA target prediction methods: Miranda (John et al., 2004) , TargetScan (Lewis et al., 2005) , PicTar (Krek et al., 2005) , or RNA22 (Miranda et al., 2006) . By using four prediction methods with relaxed stringencies, we maximized the number of miRNAs chosen to undergo the tier-2 assay to avoid missing TP53-targeting miRNAs. These analyses identified 67 miRNAs predicted to target the human p53 3 0 UTR by at least one method. Only 8 out of these 67 miRNAs downregulated reporter expression with a cutoff of 25% in the tier-1 assay (Figure 1c ; Supplementary Figure S1 ), indicating that a number of predicted miRNA-mRNA interactions are probably false positives and can be excluded by experimental validation, such as the tier-1 assay. The tier-2 assay ( Figure 1b ) was then performed to determine which of the miRNAs predicted to target TP53 downregulate the expression of Rluc located upstream of the TP53 3 0 UTR. Only three miRNAs (miR-25, miR-30d and miR-200a) downregulated both Rluc in the tier-2 assay and luc expression in the tier-1 assay by more than 25% and emerged as putative regulators of p53 (Figures 1c and d) .
We next examined the protein levels of p53 when miR-25, miR-30d, or miR-200a was overexpressed in 293T cells ( Supplementary Table S1 ). The protein levels of p53 were downregulated significantly by miR-25 and miR-30d, but not by miR-200a ( Figure 1e ). To determine whether these miRNAs target the TP53 3 0 UTR specifically, we performed a mutation analysis, in which the nucleotides corresponding to the seed sequence of each miRNA were mutated in pRL-p53UTR ( Figure 1f ). A tier-2 assay performed using mutant TP53 3 0 UTRs instead of pRL-p53UTR showed that a mutation in the corresponding miR-25 region abolished reporter regulation by miR-25, but not by miR-30d. Similar results were observed with mutations for miR-30d ( Figure 1g ), although a control mutant in which a mock miR-200a binding site was mutated did not affect reporter expression by either miR-25 or miR-30d ( Figure 1g ). These results suggest that the downregulation of the reporter gene by these miRNAs is dependent on specific segments of the TP53 3 0 UTR, which are partially complementary to the respective miRNAs. Finally, we examined TP53 mRNA levels after introduction of miRNAs. TP53 mRNA was downregulated about 60 or 85% with the introduction of miR-30d or miR-25 ( Figure 1h ), indicating that TP53 mRNA was degraded and that corresponding changes in protein levels were likely mediated by mRNA turnover. Taken together, these results suggest that TP53 is an authentic target of miR-25 and miR-30d in 293T cells.
miRNAs inhibit the effect of p53 on apoptotic cell death and G2 arrest in 293T cells One of the major end points of p53 activation is apoptosis, which partially depends on the induction of Bax. Apoptosis can be enhanced by genotoxic agents such as etoposide. We examined the protein levels of p53, p21 and Bax in 293T cells overexpressing miR-25 or miR-30d with or without etoposide treatment. We found that p53, p21 and Bax expression decreased with miRNA overexpression in the presence or absence of the DNA damaging agent (Figure 2a , left panel). As the p53-and Bax-dependent intrinsic apoptosis pathway is known to be mediated by caspase 9 (initiator caspase) and caspases 3, 6 and 7 (effector caspase) (Mayer and Oberbauer, 2003) , we measured both caspase 9 and caspase 3 and 7 activities in 293T cells expressing miRNAs in the presence or absence of etoposide. As shown in Figures 2b and c, there was a significant decrease in caspase activities when either miRNA was overexpressed in 293T cells with or without etoposide Figure 2a ). Gadd45a (growth arrest and DNA damage inducible), a protein regulated by p53, has been reported to induce cell cycle arrest at the G2-M phase (G2 arrest) (Wang et al., 1999) . In our experiment, Gadd45a was downregulated along with p53 in 293T cells transfected with either miR-25 or miR-30d (Figure 2a , right panel) and a cell cycle analysis showed that fewer cells were arrested at the G2-M phase than in the control (Figure 2d ). These data suggest that miR-25 and miR-30d downregulate the expression of p53, Bax and Gadd45a, and subsequently reduce both apoptosis and G2 arrest in 293T cells. A similar G2 arrest was observed in wt p53, non-immortalized, primary human lung fibroblast WI-38 cells (Supplementary Figure S2) .
As miR-25 is reported to target Bim in gastric cancer cells (Petrocca et al., 2008) and Barrett's esophagus (Kan et al., 2009 ) and PCAF in multiple myeloma cancer cells (Pichiorri et al., 2008) , we determined the expression of these two proteins in 293T cells. In contrast to previous reports, the expression levels of both Bim and PCAF were not altered significantly by miRNAs inhibit p53 function on apoptosis and G1 arrest in p53-null H1299 cells with ectopic p53 expression We next constructed three distinct p53 expression cassettes on the basis of pCMV-p53 carrying a wt p53 gene instead of pRL-TK with Rluc, all with wt TP53 coding sequences: one with a wt 3 0 UTR (p53/3UTRwt) and the other two with mutations that disrupt a respective miRNA-3 0 UTR interaction (p53/3UTR-mut25 and p53/3UTRmut30d). We introduced these p53 constructs and miRNAs into human lung adenocarcinoma p53-null H1299 cells and found that both miR-25 and miR-30d downregulated the expression of the ectopic p53 gene with a wt 3 0 UTR (Figure 3a ). However, p53 expression levels were not changed in cells co-transfected with a miRNA and a p53 gene with a respective mutant 3 0 UTR (Figure 3a) . A similar expression pattern was observed for the p53-regulated genes p21, Puma and Bax (Figure 3a) . We next determined cell apoptosis as both Puma and Bax were downregulated in cells having p53 with a wt 3 0 UTR but not in those with a mutant 3 0 UTR (Figure 3a ). As shown in Figures 3b and c and Bax were downregulated, apoptotic cell death was reduced in cells with each miRNA and an ectopic p53 gene with a wt 3 0 UTR. In contrast, there was no significant change in apoptosis in cells carrying a p53 gene with a mutant 3 0 UTR, which can no longer be targeted by the respective miRNA (Figure 3c ). This coincided with the unaltered expression levels of both p53 and Puma/Bax in these cells (Figure 3a) . We then performed a cell cycle analysis and found that fewer cells were arrested at the G1-S phase (G1 arrest) when miR-25 or miR-30d was co-overexpressed with the p53 gene with a wt 3 0 UTR, but not with the one with a respective mutant (Figure 3d ). This is presumably because of the functional output of the p53-regulated CDK inhibitor p21, which is significantly downregulated in cells overexpressing a miRNA-targeted TP53 gene with a wt 3 0 UTR but not in those with mutant 3 0 UTRs (Figure 3a) . These results support the view that miRNAs target p53 to downregulate Puma/Bax and p21 expression and adversely affect apoptosis and G1 arrest in H1299 cells carrying an ectopic p53 expression construct.
miRNAs inhibit the effect of p53 on cellular senescence in HCT116 cells To further determine p53 regulation by miRNAs, we used a pair of cell lines that have been widely used in studies of p53: HCT116 cells with a wtTP53 gene and HCT116 p53À/À in which both TP53 alleles are deleted (Bunz et al., 1998) . We introduced miR-25 or miR-30d into these two cell lines and monitored the expression levels of Bax, p21 and p53. We found that miRNAs downregulated the expression of p53 and two p53transactivated genes in HCT116, the cell line with a wtTP53 gene, but not in HCT116 p53À/À cells, which do not have TP53 (Figure 4a, left) , indicating that downregulation of p21 and Bax by miRNAs was p53 dependent.
We transfected p53 constructs with 3 0 UTR variants and miRNAs into HCT116 p53À/À cells and determined the expression levels of p53, p21 and Bax. We found that both miR-25 and miR-30d downregulated the expression of the ectopic p53 gene carrying a wt 3 0 UTR but not the one with a mutant (Figure 4a ). The expression of both p21 and Bax was either reduced or minimally changed, following p53 expression. We then determined cellular senescence using b-galactosidase staining, as p21 is thought to be responsible for irreversible cellular arrest, that is, senescence. As shown in Figure 4b , senescence was reduced in HCT116 cells with miRNA overexpression and lower levels of p53 and p21 (Figure 4a ). In contrast, cellular senescence was reduced in HCT116 p53À/À cells with either miRNA and an ectopic p53 gene with a wt 3 0 UTR (and lower levels of p21, Figure 4a ), but the reduction of senescence was abolished in HCT116 p53À/À cells coexpressing either miRNA or a p53 gene carrying a respective mutant 3 0 UTR (Figure 4c and Supplementary Figure  S3 ). These results suggest that miR-25 and miR-30d regulate cellular senescence by downregulating p53 expression and subsequently the expression of p21 and that such regulation depends on miRNA binding sites of TP53 3 0 UTR.
Inhibition of miRNA expression increases p53 expression and cellular apoptosis in HCT116 and A549 cells
To further investigate whether endogenous p53 expression is regulated by miRNAs, we next determined whether inhibition of miRNA expression increases p53 expression. We transfected miRNA inhibitors into two Figure 4 miRNAs inhibit p53 cellular senescence expression in HCT116 and HCT116 p53À/À cells. (a) p53, p21 and Bax expression in HCT116 and HCT116 p53À/À cells with miRNA overexpression. (b) miRNAs inhibit cellular senescence in HCT116 cells. (c) miRNAs inhibit cellular senescence in HCT116 p53À/À cells expressing an ectopic wt p53 with a wt 3 0 UTR, but not those with mutant 3 0 UTRs. The bar graphs in (b) and (c) represent three independent runs. The 'control' experiment in (c) was performed using parental vectors only (1:1 of miRNA empty vector and p53 empty vector). The y axis in the graphs denotes the number of senescencepositive cells per microscope field. *Pp0.05 with n ¼ 6.
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M Kumar et al cell lines, HCT116 and A549, both possessing a wt p53 gene. We observed that the endogenous level of p53 protein was elevated when any of the inhibitors to miR-25 or miR-30d was introduced (Figure 5a ). p21 and Puma were also upregulated in both cell lines ( Figures  5a and c) . Furthermore, an increase in apoptosis was observed, coinciding with the elevated levels of Puma in both HCT116 and A549 cells (Figures 5b and d) .
Inhibition of miRNA expression increases p53 expression and cellular apoptosis in multiple myeloma cells
Most of the miRNA expression profiling in cancers conducted to date does not distinguish tumors with wt TP53 from those with TP53 mutations; hence, the association of miRNA dysregulation and p53 inactivation may not be revealed if overexpression of miRNAs only inactivates the wt TP53 gene. We reasoned that if these miRNAs were involved in p53 inactivation, they could be overexpressed in cancers with an extremely low p53 mutation rate. Multiple myeloma is a neoplasm characterized by excessive infiltration of abnormal plasma cells in the bone marrow. Various studies of p53 mutations in multiple myeloma with clinical heterogeneity in the study cohorts and small sample sizes reported a prevalence of p53 mutation ranging from 0 to 20% (Fonseca et al., 2004) . The latest comprehensive study with the largest number of newly diagnosed patients reported that TP53 mutations are rare, as only 9 of 268 samples (3%) tested were positive for monoallelic mutations (Chng et al., 2007) . Biallelic deletion of TP53 is observed in only 2% of patients (Xiong et al., 2008) . Moreover, other known mechanisms of p53 inactivation also have relatively low incidence in multiple myeloma ( Supplementary Table  S2 ). It has been reported that miR-25 is overexpressed in primary plasma cells from multiple myeloma patients (n ¼ 16) by B71-fold (P ¼ 3E-07) and miR-25 is indeed the most upregulated miRNA (Pichiorri et al., 2008) . In addition, miR-125b and miR-30d (but not miR-504) are also upregulated B5.6-fold (P ¼ 0.05) and B2.1-fold (P ¼ 0.04), respectively (Pichiorri et al., 2008) . We found that miR-25 and miR-30d were overexpressed B6.3and B11.2-fold (mean values; P ¼ 0.0027 and 0.018) in plasma cells from a larger number of multiple myeloma patients (n ¼ 31) compared with those from healthy donors (n ¼ 6) (Figure 6a ). In addition, we determined the TP53 mRNA levels in plasma cells and found that TP53 mRNA is lower in plasma cells of multiple myeloma patients than in healthy donors (mean value is B25% of that of the control; P ¼ 0.0063; Figure 6a ). TP53 mRNA levels were detectable in all myeloma specimens, indicating that there was no TP53 biallelic deletion in this cohort. We determined whether there was an inverse correlation between miRNA expression and TP53 mRNA in multiple myeloma as measured by Pearson's correlation. miR-25 expression was moderately inversely correlated with TP53 mRNA levels (coefficient ¼ À0.22, P ¼ 0.026) and so is miR-30d (coefficient ¼ À0.10, P ¼ 0.037). Given that miR-25 and miR-30d downregulate p53 expression through reduction in p53 mRNA levels (Figure 1h ), this result indicates the importance of miRNA overexpression in lowering p53 expression.
To further test whether miRNAs regulate endogenous p53 expression in multiple myeloma, we introduced miRNA inhibitors into an established multiple myeloma cell line H929 with a wt p53 gene. We found that the endogenous level of p53 protein was elevated when any of the inhibitors to miR-25 or miR-30d was introduced (Figure 6b ). Puma was also upregulated (Figure 6b ). An increase in apoptosis was observed in H929 cells with inhibitors to any of the two miRNAs (Figure 6c ). Taken together, these data suggest that dysregulation of miR-25 and miR-30d is pathologically important for p53 function in H929 cells. Thus, inhibition of miRNA to activate p53 could be a therapeutic tool for multiple myeloma intervention.
Discussion
The investigation of mechanisms of p53 inactivation in tumors has been the focus of intense interest as it may offer a clue as to where malignancy initiates (Vousden and Prives, 2009) . Several miRNAs, such as miR-372 and miR-373, miR-29a, b, c and miR-34a, b, c, have been reported to be important components of the p53 transcriptional network. The identification of miRNAs that directly target TP53 is critical for understanding why approximately 50% of cells with wtTP53 have developed malignancies. In this study, we identify two miRNAs, miR-25 and miR-30d, which interact with the 3 0 UTR of the human TP53 gene to negatively regulate p53 expression. Downregulation of p53 protein and its transactivational genes such as p21, Bax, Puma and Gadd45a by these miRNAs is sufficient to reduce cellular apoptosis, cell cycle arrest and senescence. These findings suggest an important role for miR-25 and miR-30d in the regulation of the p53 tumor suppression As p53 is well integrated in a complex molecular network and involved in a number of positive and negative feedback loops (Harris and Levine, 2005) , we were interested in determining whether p53 status affects the expression of miR-25 or miR-30d. We transfected pCMV-p53 carrying a functional p53 gene or pCMV-p53m153 with an inactive TP53 into 293T cells and H1299 cells and determined the expression of miRNAs by q-PCR. The expression of miR-25 and miR-30d was not changed in either cell line. This result indicated that the expression of miR-25 and miR-30d is not regulated by p53. Similar results were reported by another group in a p53 temperature-sensitive cell line (Raver-Shapira et al., 2007) , indicating that p53 is unlikely to regulate the expression of TP53-targeting miR-25 or miR-30d. It is consistent with the fact that there are no p53 TREs in the promoter of miR-25, which is in the same transcriptional unit with MCM7 (Suzuki et al., 1998) or miR-30d. It is noteworthy that other members of the miR-25 and miR-30 gene family were not identified to target p53 in our screen assay, although they have the same seed sequence as that of miR-25 and miR-30d. These miRNAs include miR-92a, b and miR-30a, b, c, e ( Supplementary Table S3 ). This may largely be because of the difference in the 3 0 portion of these miRNAs. It has been proposed that 3-4 contiguous Watson-Crick pairs uninterrupted by bulges, mismatches, or wobbles, involving the 3 0 portion of miRNAs and the UTR of a target gene, are important for miRNA-target interaction (Bartel, 2009) . These base pairs are called 3 0 supplementary pairing. We noted that there is 3 0 supplementary pairing between p53 3 0 UTR and miR-25/miR-30d, but no supplementary pairing between 3 0 UTR and miR-92a, b/miR-30a, b, c, e ( Supplementary  Table S3 ). These minor differences were reflected by our tier-1 assay in which miR-92a and miR-30a did not downregulate p53-dependent reporter activity (Supplementary Figure S1 ). We also recognize that miR-125b and miR-504, two known p53 regulators, were not scored in our method, which indicates that the screening assay used in this study is by no means exhaustive and may have cell-line specificity limitations (Supplementary Data Set 1).
Interestingly, three TP53-targeting miRNAs, miR-25 and miR-30d in our study and miR-125b in a previous study (Le et al., 2009) , are evolutionally conserved in fly, zebra fish, mouse and humans and they are grouped into miR-125, miR-25 and miR-30 gene families (Griffiths-Jones et al., 2006) . The miR-504 gene located on chromosome X, on the other hand, is mammalian specific. The mature sequences of these four miRNAs from mouse are identical to those of human and the stem-loop pre-miRNAs of miR-25 from mouse are the same as those from human. However, the TP53 3 0 UTRs from mice and humans vary in size and sequence, and none of the four miRNAs are predicted to target mouse TP53 ( Supplementary Table S4 ). The human TP53 3 0 UTR (Genbank No. NM_000546) is 1207 nts, whereas the mouse (NM_011640) is only 431 nts; and they share little sequence identity, except for a B100 nt fragment (B77% identity). In contrast, both the coding DNA sequence and amino-acid sequence of p53 from mouse (1173 nts & 390 amino acid) and humans (1182 nts & 393 amino acid) are highly conserved with B80% identity. This indicates that p53 regulation by miR-25, miR-30d, miR-125b and miR-504 via the 3 0 UTR does not serve the same role in mice. This could contribute to differences in tumor development between humans and mouse.
p53 function is known to be disrupted in the majority of human cancers. Yet, in some tumors, p53 mutation rates are extremely low. For instance, only a minute subset of multiple myeloma cases has TP53 genetic alterations (3% mutation and 2% biallelic deletion) at the time of diagnosis. Should disrupting p53 function be indispensable to tumorigenesis, there would be other mechanisms of p53 inactivation. We have shown that miR-25 and miR-30d overexpression is inversely correlated with lower TP53 mRNA levels in plasma cells from multiple myeloma patients compared with those from healthy donors. Moreover, inhibition of miR-25 or miR-30d increased p53 and Puma expression levels and led to elevated cellular apoptosis. These results suggest that p53 inactivation by overexpressed miRNAs may be a crucial early step that primes plasma cells to malignancy, as high levels of miRNAs could prevent p53 from guarding the genome. Beyond multiple myeloma, miR-25 and miR-30d are also upregulated in prostate, pancreatic and stomach tumors when compared with normal tissues (Yanaihara et al., 2006) . It has been reported that mutations of TP53 occur infrequently in early invasive prostate carcinoma (Voeller et al., 1994; Prendergast et al., 1996) . Thus, categorizing cancers on the basis of TP53 gene status may uncover more intriguing miRNA expression patterns and reveal the power of miRNAs as biomarkers and drug targets.
To summarize, the arsenal of p53 regulators includes not only proteins such as Mdm2 and Mdm4 but also miRNAs. Most known p53 regulation mechanisms by proteins are post-translational, but miRNAs, including miR-25, miR-30d, miR-125b and miR-504, regulate p53 expression posttranscriptionally by interacting with its 3 0 UTR. Their ability to function directly on p53 and adversely affect apoptosis, cell cycle arrest and senescence of cancer cells makes them attractive candidates as drug targets. As the p53 gene is only mutated in about half of all human cancers, it could be inactivated by miRNA overexpression in malignancies such as multiple myeloma with little p53 mutations. Determination of TP53 gene status and miRNA expression and manipulation of miRNA levels in human tumors may therefore enable better cancer diagnosis, prognosis and therapy.
Materials and methods
Plasmid constructs
The construction of the genetic library for miRNA minigenes is described elsewhere and all constructs are available at Genecopoeia, Inc. (Germantown, MD, USA). The 3 0 UTR of TP53 was PCR amplified from genomic DNA and cloned into pRL-TK (Promega, Madison, WI, USA) downstream of the miRNAs target TP53 M Kumar et al Renilla luciferase gene. Mutations in pRL-p53UTRmut were cloned by PCR to contain the following sequences: 5 0 -ACGTTAT-3 0 (position 92-98, mutated from 5 0 -TGCAATA-3 0 ) for miR-25, 5 0 -CAAATGT-3 0 (position 287-293, mutated from 5 0 -GTTTACA-3 0 ) for miR-30d and 5 0 -GTCACAA-3 0 (position 960-966, mutated from 5 0 -CAGTGTT-3 0 ) for miR-200a. For constructs expressing TP53 and its 3 0 UTR variants, the wt or mutant 3 0 UTR of TP53 was cut from pRL-p53UTR or its mutant and cloned downstream of the p53 expression cassette of pCMV-p53 (Clontech, Mountain View, CA, USA). All constructs were confirmed by DNA sequencing.
Statistical analyses
All values in Figures 1c-e, g and h, 2c, 3c , 4b and c, 5b and d, and 6c were represented as means with s.e.m. from three to six independent experiments. Statistical analyses were performed using Student's t-test with results considered statistically significant at Pp0.05. Pearson's correlation analyses in Figure 6a were performed using SPSS 11.5 (SPSS, Inc., Chicago, IL, USA). Cell culture, western blotting, qRT-PCR, cell cycle analysis, apoptosis and senescence assays were performed using routine procedures and details are provided in Supplementary Text 1.
